Search - tctmd.com

Displaying 401 - 419 of 419

Sort: Relevancy | Date

News Daily News

研究认为有数据支持针对患者风险而非 LDL 胆固醇目标进行治疗

Michael O'Riordan

February 15, 2016

News Daily News

Según un Informe los Datos Avalan Tratar el Riesgo de los Pacientes No las Dianas de Colesterol LBD

Michael O'Riordan

February 15, 2016

News Daily News

Data Support Treating Patient Risk, Not LDL Cholesterol Targets, Paper Argues

Michael O'Riordan

February 15, 2016

News Daily News

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Michael O'Riordan

January 26, 2016

News Daily News

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Michael O'Riordan

January 26, 2016

News Daily News

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Michael O'Riordan

January 26, 2016

News Features

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Michael O'Riordan

January 25, 2016

News Daily News

Perioperative Statin Therapy Improves Clinical Outcomes Following CABG Surgery

Michael O'Riordan

January 17, 2016

News Daily News

USPSTF Issues Preliminary Recommendations on Statin Use in Primary Prevention

Michael O'Riordan

January 12, 2016

News Daily News

心梗后、PCI 后以及 CAD 患者的他汀类药物绩效指标发生修订

Michael O'Riordan

December 20, 2015

News Daily News

Revisión de las Métricas de Rendimiento para el Uso de Estatinas Post-IM, Post-PCI en Pacientes EAC

Michael O'Riordan

December 20, 2015

News Daily News

Performance Metrics Revised for Statins Post-MI, After PCI, and in CAD Patients

Michael O'Riordan

December 20, 2015

News Daily News

依泽替米贝减少心血管事件的说法未能获得 FDA 顾问委员会的支持

Michael O'Riordan

December 15, 2015

News Daily News

Un Comité Asesor de la FDA No Avala la Afirmación de que Ezetimibe Reduce los Episodios CV

Michael O'Riordan

December 15, 2015

News Daily News

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Michael O'Riordan

December 15, 2015

News Daily News

ACC, AHA Risk-Based Approach Remains Best Method for Statin Allocation in Primary Prevention

Michael O'Riordan

December 13, 2015

News Daily News

与他汀类药物相关的负面新闻与停药和心血管风险增加有关

Michael O'Riordan

December 02, 2015

News Daily News

Negative Statin-Related News Linked With Drug Discontinuation, Increased CV Risk

Michael O'Riordan

December 02, 2015

News Daily News

Las Noticias Negativas sobre las Estatinas se asociaron a su Interrupción y a Más Riesgo CV

Michael O'Riordan

December 02, 2015

Advertisement

研究认为有数据支持针对患者风险而非 LDL 胆固醇目标进行治疗

Según un Informe los Datos Avalan Tratar el Riesgo de los Pacientes No las Dianas de Colesterol LBD

Data Support Treating Patient Risk, Not LDL Cholesterol Targets, Paper Argues

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Perioperative Statin Therapy Improves Clinical Outcomes Following CABG Surgery

USPSTF Issues Preliminary Recommendations on Statin Use in Primary Prevention

心梗后、PCI 后以及 CAD 患者的他汀类药物绩效指标发生修订

Revisión de las Métricas de Rendimiento para el Uso de Estatinas Post-IM, Post-PCI en Pacientes EAC

Performance Metrics Revised for Statins Post-MI, After PCI, and in CAD Patients

依泽替米贝减少心血管事件的说法未能获得 FDA 顾问委员会的支持

Un Comité Asesor de la FDA No Avala la Afirmación de que Ezetimibe Reduce los Episodios CV

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

ACC, AHA Risk-Based Approach Remains Best Method for Statin Allocation in Primary Prevention

与他汀类药物相关的负面新闻与停药和心血管风险增加有关

Negative Statin-Related News Linked With Drug Discontinuation, Increased CV Risk

Las Noticias Negativas sobre las Estatinas se asociaron a su Interrupción y a Más Riesgo CV

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content